X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2017 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare GSK Pharma with Dr. Reddys - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

GSK PHARMA vs DR. REDDYS LAB - Comparison Results

GSK PHARMA    Change

GSK Pharma is one of the leading MNC pharma companies in the Indian market. It is a 50.7% subsidiary of GlaxoSmithKline Plc, one of the world's largest pharma companies. GSK Pharma's product portfolio boasts of some of the leading brands like Augment... More

DR. REDDYS LAB 
   Change

Dr. Reddy's is a leading pharmaceutical company in the country with presence across the value chain. While the global generics business accounted for 69% of total revenues in FY12, the PSAI business (Pharma Services and Active Ingredients - PSAI) con... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    GSK PHARMA DR. REDDYS LAB GSK PHARMA/
DR. REDDYS LAB
 
P/E (TTM) x 59.9 26.6 225.4% View Chart
P/BV x 11.7 2.7 429.0% View Chart
Dividend Yield % 2.1 1.0 202.9%  

Financials

 GSK PHARMA   DR. REDDYS LAB
EQUITY SHARE DATA
    GSK PHARMA
Mar-16
DR. REDDYS LAB
Mar-16
GSK PHARMA/
DR. REDDYS LAB
5-Yr Chart
Click to enlarge
High Rs3,8504,383 87.8%   
Low Rs2,9662,750 107.8%   
Sales per share (Unadj.) Rs332.3920.1 36.1%  
Earnings per share (Unadj.) Rs44.3126.1 35.1%  
Cash flow per share (Unadj.) Rs47.2183.0 25.8%  
Dividends per share (Unadj.) Rs50.0020.00 250.0%  
Dividend yield (eoy) %1.50.6 261.6%  
Book value per share (Unadj.) Rs202.7685.8 29.6%  
Shares outstanding (eoy) m84.70170.61 49.6%   
Bonus/Rights/Conversions -ESOP-  
Price / Sales ratio x10.33.9 264.5%   
Avg P/E ratio x76.928.3 272.0%  
P/CF ratio (eoy) x72.219.5 370.2%  
Price / Book Value ratio x16.85.2 323.2%  
Dividend payout %112.915.9 711.7%   
Avg Mkt Cap Rs m288,643608,481 47.4%   
No. of employees `0004.621.7 21.3%   
Total wages/salary Rs m4,43431,874 13.9%   
Avg. sales/employee Rs Th6,104.57,244.4 84.3%   
Avg. wages/employee Rs Th961.61,470.9 65.4%   
Avg. net profit/employee Rs Th813.7992.8 82.0%   
INCOME DATA
Net Sales Rs m28,148156,978 17.9%  
Other income Rs m1,2182,693 45.2%   
Total revenues Rs m29,366159,671 18.4%   
Gross profit Rs m4,77434,587 13.8%  
Depreciation Rs m2489,705 2.6%   
Interest Rs m0824 0.0%   
Profit before tax Rs m5,74426,751 21.5%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m260-   
Tax Rs m2,0185,237 38.5%   
Profit after tax Rs m3,75221,514 17.4%  
Gross profit margin %17.022.0 77.0%  
Effective tax rate %35.119.6 179.5%   
Net profit margin %13.313.7 97.3%  
BALANCE SHEET DATA
Current assets Rs m21,462118,201 18.2%   
Current liabilities Rs m10,53668,368 15.4%   
Net working cap to sales %38.831.7 122.3%  
Current ratio x2.01.7 117.8%  
Inventory Days Days6860 112.8%  
Debtors Days Days1697 16.9%  
Net fixed assets Rs m4,71772,265 6.5%   
Share capital Rs m847853 99.3%   
"Free" reserves Rs m16,308111,548 14.6%   
Net worth Rs m17,171117,009 14.7%   
Long term debt Rs m1610,690 0.1%   
Total assets Rs m30,620200,104 15.3%  
Interest coverage xNM33.5-  
Debt to equity ratio x00.1 1.0%  
Sales to assets ratio x0.90.8 117.2%   
Return on assets %12.311.2 109.8%  
Return on equity %21.918.4 118.8%  
Return on capital %33.621.6 155.5%  
Exports to sales %046.3 0.0%   
Imports to sales %15.19.0 168.2%   
Exports (fob) Rs m472,618 0.0%   
Imports (cif) Rs m4,23714,050 30.2%   
Fx inflow Rs m51975,405 0.7%   
Fx outflow Rs m8,32027,115 30.7%   
Net fx Rs m-7,80148,290 -16.2%   
CASH FLOW
From Operations Rs m1,38640,476 3.4%  
From Investments Rs m5,010-19,421 -25.8%  
From Financial Activity Rs m-6,383-17,009 37.5%  
Net Cashflow Rs m124,046 0.3%  

Share Holding

Indian Promoters % 0.0 25.5 -  
Foreign collaborators % 50.7 0.0 -  
Indian inst/Mut Fund % 10.2 5.4 188.9%  
FIIs % 23.8 35.3 67.4%  
ADR/GDR % 0.0 18.5 -  
Free float % 15.4 15.3 100.7%  
Shareholders   102,036 75,885 134.5%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare GSK PHARMA With:   STRIDES SHASUN LTD  AJANTA PHARMA  ALEMBIC LTD  DR. DATSONS LABS  CADILA HEALTHCARE  

Compare GSK PHARMA With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Post Noon Sell-Off; Infosys Falls 5.4%(Closing)

Share markets in India witnessed a sharp fall in the final minutes of trade. At the closing bell, the BSE Sensex closed lower by 266 points. While, the NSE Nifty finished lower by 83 points.

Related Views on News

Dr Reddy's: US Pressure Continues to Haunt (Quarterly Results Update - Detailed)

Aug 8, 2017

Profits plunge due to higher raw material costs.

Dr Reddy's: Major Business Segments Come Under Pressure (Quarterly Results Update - Detailed)

Sep 12, 2016

Dr Reddy's has announced the results for first quarter of FY17 (1QFY17). The company has reported decline in the sales by 13.9% YoY while net profits declined by 79.8 % YoY.

Sun Pharma: Bottomline Slips into the Red Amidst Challenging Environment (Quarterly Results Update - Detailed)

Aug 14, 2017

A challenging environment and one-time expense pushes Sun Pharma into a loss in the first quarter.

Lupin: Bigger Challenges or Bigger Margin of Safety? (Quarterly Results Update - Detailed)

Aug 14, 2017

GST impact coupled with price erosion in US leads to lower profits for the quarter.

Biocon: Lower Licensing Income Leads to Muted Growth for the Quarter (Quarterly Results Update - Detailed)

Jun 23, 2017

Net Profit lower due to exceptional items in the previous year.

More Views on News

Most Popular

A 'Backdoor' to Multibaggers: It's Like Investing in Asian Paints Ten Years Ago(The 5 Minute Wrapup)

Aug 10, 2017

Don't miss these proxy bets on growing companies or in a few years you will be looking back with regret.

The Most Profitable Investment in the History of the World(Vivek Kaul's Diary)

Aug 8, 2017

'Yes, it looks like a bubble. And, yes, it's like buying a lottery ticket. But there's something happening that has never happened before. It's an evolutionary leap in money itself.'

Should You Invest In Bharat-22 ETF? Know Here...(Outside View)

Aug 8, 2017

Bharat-22 is one of the most diverse ETFs offered so far by the Government. Know here if you should invest...

Signs of Life in the India VIX(Daily Profit Hunter)

Aug 12, 2017

The India VIX is up 36% in the last week. Fear has gone up but is still low by historical standards.

Bitcoin Continues Stellar Rise(Chart Of The Day)

Aug 10, 2017

Bitcoin hits an all-time high, is there more upside left?

More

Become A Smarter Investor In
Just 5 Minutes

Multibagger Stocks Guide 2017
Get our special report, Multibagger Stocks Guide (2017 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

GSK PHARMA SHARE PRICE


Aug 21, 2017 (Close)

TRACK GSK PHARMA

  • Track your investment in GSK PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

GSK PHARMA - GLENMARK PHARMA COMPARISON

COMPARE GSK PHARMA WITH

MARKET STATS